NTLA Intellia Therapeutics Inc.

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates

CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its first quarter 2020 financial results and operational highlights in a conference call on May 7, 2020 at 8 a.m. ET.

To join the call:

  • U.S. callers should dial 1-877-317-6789 and use conference ID# 10141541, approximately five minutes before the call.
  • International callers should dial 1-412-317-6789 and use conference ID# 10141541, approximately five minutes before the call.

A replay of the call will be available through the Events and Presentations page of the Investors & Media section of the company’s website at , beginning on May 7, 2020 at 12 p.m. ET.

About Intellia Therapeutics

Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients’ diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at and follow us on Twitter @intelliatweets.

Intellia Contacts:

Investor Contact:

Lina Li

Associate Director, Investor Relations



Media Contact:

Jennifer Mound Smoter

Senior Vice President, External Affairs & Communications



EN
30/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intellia Therapeutics Inc.

 PRESS RELEASE

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAG...

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the first patient dosed in the global pivotal, Phase 3 MAGNITUDE trial of NTLA-2001. NTLA-2001 is an investigational in vivo CRISPR-based therapy designed as a single-dose treatment to i...

David Carlson ... (+4)
  • David Carlson
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Fina...

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in Q1 2024Expect to initiate the Phase 3 study of NTLA-2002 for the treatment of hereditary angioedema (HAE) in 2H24Plan to present new clinical data in 2024 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies, including NTLA-2002 Phase 2 results Published positive interim results from the Phase 1 study of ...

 PRESS RELEASE

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Colla...

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) to extend the reach of gene editing to disease-causing targets in the lung CAMBRIDGE, Mass. and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing me...

David Carlson ... (+4)
  • David Carlson
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

ResearchPool Subscriptions

Get the most out of your insights

Get in touch